

AP20 Received PTO 04 AUG 2006

Application Data Sheet 37 CFR 1.76		Attorney Docket Number 101361-1P US	Application Number
Title of Invention	SUBSTITUTED THIENO- AND THIAZOLO- [2,3-d]PYRIMIDINES AND [2,3-c]PYRIDINES AS INHIBITORS OF TIE2		
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.			

Secrecy Order 37 CFR 5.2

- ☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Applicant Information:

Applicant 1				
Applicant Authority <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
	Clifford	David	JONES	
Residence Information (Select One) <input type="radio"/> US Residency <input checked="" type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
City	Macclesfield	Country Of Residenceⁱ	UK	
Citizenship under 37 CFR 1.41(b)ⁱ		GB		
Mailing Address of Applicant:				
Address 1		AstraZeneca R&D Alderley		
Address 2		Alderley Park		
City	Macclesfield, Cheshire	State/Province		
Postal Code	SK10 4TG	Countryⁱ	UK	
Applicant 2				
Applicant Authority <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
	Richard	William Arthur	LUKE	
Residence Information (Select One) <input type="radio"/> US Residency <input checked="" type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
City	Macclesfield	Country Of Residenceⁱ	UK	
Citizenship under 37 CFR 1.41(b)ⁱ		GB		
Mailing Address of Applicant:				
Address 1		AstraZeneca R&D Alderley		
Address 2		Alderley Park		
City	Macclesfield, Cheshire	State/Province		
Postal Code	SK10 4TG	Countryⁱ	UK	
Applicant 3				
Applicant Authority <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
	William		MCCOULL	
Residence Information (Select One) <input type="radio"/> US Residency <input checked="" type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
City	Macclesfield	Country Of Residenceⁱ	UK	

Application Data Sheet 37 CFR 1.76		Attorney Docket Number		101361-1P US	
		Application Number			
Title of Invention	SUBSTITUTED THIENO- AND THIAZOLO- [2,3-d]PYRIMIDINES AND [2,3-c]PYRIDINES AS INHIBITORS OF TIE2				
Citizenship under 37 CFR 1.41(b) i					
Mailing Address of Applicant:					
Address 1		AstraZeneca R&D Alderley			
Address 2		Alderley Park			
City	Macclesfield, Cheshire		State/Province		
Postal Code	SK10 4TG	Countryi	UK		
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button.					<input type="button" value="Add"/>

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).			
<input type="checkbox"/> An Address is being provided for the correspondence information of this application.			
Customer Number	44992		
Email Address		<input type="button" value="Add Email"/>	<input type="button" value="Remove Email"/>

Application Information:

Title of the Invention	SUBSTITUTED THIENO- AND THIAZOLO- [2,3-d]PYRIMIDINES AND [2,3-c]PYRIDINES AS INHIBITORS OF TIE2		
Attorney Docket Number	101361-1P US	Small Entity Status Claimed <input type="checkbox"/>	
Application Type	Nonprovisional		
Subject Matter	Utility		
Suggested Class (if any)	N/A	Sub Class (if any)	N/A
Suggested Technology Center (if any)			
Total Number of Drawing Sheets (if any)		Suggested Figure for Publication (if any)	
Publication Information:			
<input type="checkbox"/> Request Early Publication (Fee required at time of Request 37 CFR 1.219)			
<input type="checkbox"/> Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not been and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.			

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.			
Please Select One:	<input checked="" type="radio"/> Customer Number	<input type="radio"/> US Patent Practitioner	<input type="radio"/> US Representative (37 CFR 11.9)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	101361-1P US
		Application Number	
Title of Invention	SUBSTITUTED THIENO- AND THIAZOLO- [2,3-d]PYRIMIDINES AND [2,3-c]PYRIDINES AS INHIBITORS OF TIE2		
Customer Number	44992		

Domestic Priority Information:

This section allows for the applicant to claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c). Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification.

Prior Application Status	Pending	Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
	a 371 of international	PCT/GB2005/000339	2005-02-01
Additional Domestic Priority Data may be generated within this form by selecting the Add button.			

Foreign Priority Information:

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).

			Remove
Application Number	Country ⁱ	Parent Filing Date (YYYY-MM-DD)	Priority Claimed
0402518.5	GB	2004-02-05	<input checked="" type="radio"/> Yes <input type="radio"/> No
Additional Foreign Priority Data may be generated within this form by selecting the Add button.			

Assignee Information:

Providing this information in the application data sheet does not substitute for compliance with any requirement of part 3 of Title 37 of the CFR to have an assignment recorded in the Office.

Assignee 1

If the Assignee is an Organization check here. ☒

Organization Name AstraZeneca AB

Mailing Address Information:


Address 1	SE-151 85		
Address 2			
City	Sodertalje	State/Province	
Country ⁱ	SE	Postal Code	
Phone Number	46855326000	Fax Number	46855328820
Email Address			

Additional Assignee Data may be generated within this form by selecting the **Add** button.

Signature:

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number		101361-1P US	
		Application Number			
Title of Invention		SUBSTITUTED THIENO- AND THIAZOLO- [2,3-d]PYRIMIDINES AND [2,3-c]PYRIDINES AS INHIBITORS OF TIE2			
Signature				Date (YYYY-MM-DD)	2006-08-04
First Name	Carol	Last Name	Loeschorn	Registration Number	35590

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**